Northeast Financial Consultants Inc Clearside Biomedical, Inc. Transaction History
Northeast Financial Consultants Inc
- $2.4 Billion
- Q2 2025
A detailed history of Northeast Financial Consultants Inc transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Northeast Financial Consultants Inc holds 93,000 shares of CLSD stock, worth $367,350. This represents 0.0% of its overall portfolio holdings.
Number of Shares
93,000
Previous 93,000
-0.0%
Holding current value
$367,350
Previous $85,000
12.94%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding CLSD
# of Institutions
19Shares Held
3.99MCall Options Held
0Put Options Held
0-
Act Capital Management, LLC Wayne, PA2.2MShares$8.68 Million3.43% of portfolio
-
Black Rock Inc. New York, NY798KShares$3.15 Million0.0% of portfolio
-
Carmignac Gestion Paris, I0101KShares$397,1960.01% of portfolio
-
Captrust Financial Advisors Raleigh, NC87KShares$343,6500.0% of portfolio
-
Credit Suisse Ag Zurich, V825KShares$98,7500.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $238M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...